Non-small-cell lung cancer is a term that encompasses a number of subtypes of lung cancer. In recent years, several intracellular pathways have been studied in order to discover a potential target for novel anticancer therapies such as anaplastic lymphoma kinase (ALK) and reactive oxygen species 1 (ROS1). Increased interest in oncologic treatment research has resulted from the observation that ALK- and ROS1-associated tyrosine kinases show molecular analogies in some of their domains. This discovery led to the hypothesis that target therapy against ALK translocation could have efficacy also in ROS1-positive tumors. Crizotinib is an oral tyrosine kinase inhibitor that binds the ALK tyrosine kinase domain, blocking its function. We report the case of a woman with heavily pretreated metastatic lung adenocarcinoma harboring ROS1 positivity who experienced a prolonged and dramatic clinical benefit from crizotinib therapy.
Tumori 2015; 101(3): e103 - e106
Article Type: CASE REPORT
AuthorsPaolo Petreni, Francesca Mazzoni, Giulia Meoni, Alice Lunghi, Fabiana Letizia Cecere, Andrea Muto, Francesco Di Costanzo
- • Accepted on 02/12/2014
- • Available online on 11/04/2015
- • Published online on 25/06/2015
This article is available as full text PDF.
- Petreni, Paolo [PubMed] [Google Scholar] , * Corresponding Author (email@example.com)
- Mazzoni, Francesca [PubMed] [Google Scholar]
- Meoni, Giulia [PubMed] [Google Scholar]
- Lunghi, Alice [PubMed] [Google Scholar]
- Cecere, Fabiana Letizia [PubMed] [Google Scholar]
- Muto, Andrea [PubMed] [Google Scholar]
- Di Costanzo, Francesco [PubMed] [Google Scholar]
Department of Medical Oncology, Careggi University Hospital, Florence - Italy